Read this manager's filing book
Disclosed positions
Siren, L.L.C.: source evidence dated 2026-08-14T03:59:59.999Z.
- Issuer
- Scholar Rock Holding Corp
- Ticker
- SRRK
- Class
- COM
- Reported value
- $526,625,715
- Reported amount
- 9,575,013
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0002005245-26-000008Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| Scholar Rock Holding Corp | SRRK | COM | $526,625,715 | 9,575,013 | SH | None |
| Kymera Therapeutics Inc | KYMR | COM | $336,651,626 | 2,935,830 | SH | None |
| Erasca Inc | ERAS | COM | $208,807,348 | 11,397,781 | SH | None |
| Veradermics Inc | MANE | COMMON STOCK | $203,511,680 | 1,655,374 | SH | None |
| Tango Therapeutics Inc | TNGX | COM | $193,166,919 | 6,179,364 | SH | None |
| Revolution Medicines Inc | RVMD | COM | $168,552,000 | 900,000 | SH | None |
| Bicara Therapeutics Inc | BCAX | COM | $166,352,179 | 5,602,970 | SH | None |
| Arrowhead Pharmaceuticals Inc | ARWR | COM | $139,828,449 | 1,715,476 | SH | None |
| BeOne Medicines AG | ONC | SPONSORED ADS | $132,511,050 | 465,000 | SH | None |
| Edgewise Therapeutics Inc | EWTX | COM | $129,391,476 | 3,184,629 | SH | None |
| Rhythm Pharmaceuticals Inc | RYTM | COM | $126,160,613 | 1,136,275 | SH | None |
| Lexicon Pharmaceuticals Inc | LXRX | COM NEW | $106,328,443 | 44,303,518 | SH | None |
| Enliven Therapeutics Inc | ELVN | COM | $90,051,358 | 1,774,411 | SH | None |
| Spyre Therapeutics Inc | SYRE | COM NEW | $85,992,130 | 968,598 | SH | None |
| Parabilis Medicines Inc | PBLS | COM | $81,898,129 | 2,992,259 | SH | None |
| Xenon Pharmaceuticals Inc | XENE | COM | $79,588,523 | 1,318,564 | SH | None |
| Solid Biosciences Inc | SLDB | COM NEW | $76,827,146 | 7,690,405 | SH | None |
| Abivax SA | ABVX | SPONSORED ADS | $76,757,760 | 576,000 | SH | None |
| Hemab Therapeutics Holdings Inc | COAG | COM SHS | $76,649,413 | 2,086,834 | SH | None |
| Arcus Biosciences Inc | RCUS | COM | $74,621,857 | 2,420,430 | SH | None |
| Cogent Biosciences Inc | COGT | COM | $71,954,097 | 1,859,279 | SH | None |
| Relay Therapeutics Inc | RLAY | COM | $68,291,500 | 3,650,000 | SH | None |
| Taysha Gene Therapies Inc | TSHA | COM SHS | $67,055,203 | 9,846,579 | SH | None |
| Definium Therapeutics Inc | DFTX | COM SHS | $66,772,951 | 1,419,493 | SH | None |
| Stoke Therapeutics Inc | STOK | COM | $65,287,754 | 1,995,347 | SH | None |
| Disc Medicine Inc | IRON | COM | $64,977,649 | 888,401 | SH | None |
| Cytokinetics Inc | CYTK | COM NEW | $64,655,121 | 758,952 | SH | None |
| Septerna Inc | SEPN | COM | $63,631,000 | 1,900,000 | SH | None |
| Olema Pharmaceuticals Inc | OLMA | COM | $60,760,432 | 4,856,949 | SH | None |
| Crinetics Pharmaceuticals Inc | CRNX | COM | $53,165,887 | 1,420,788 | SH | None |
| Kailera Therapeutics Inc | KLRA | COMMON STOCK | $48,780,721 | 2,214,286 | SH | None |
| Dyne Therapeutics, Inc | DYN | COM | $47,287,866 | 2,129,125 | SH | None |
| Structure Therapeutics Inc | GPCR | SPONSORED ADS | $46,852,139 | 872,967 | SH | None |
| Taboola.com Ltd | TBLA | ORD SHS | $42,117,050 | 8,423,410 | SH | None |
| Palvella Therapeutics Inc | PVLA | COM | $39,348,858 | 257,485 | SH | None |
| Silence Therapeutics PLC | SLN | ADS | $36,359,589 | 3,311,438 | SH | None |
| Denali Therapeutics Inc | DNLI | COM | $35,918,314 | 1,396,513 | SH | None |
| Remitly Global Inc | RELY | COM | $34,584,703 | 1,543,271 | SH | None |
| Cullinan Therapeutics Inc | CGEM | COM | $34,478,996 | 1,893,410 | SH | None |
| Capital One Finl Corp | COF | COM | $34,429,401 | 171,615 | SH | None |
| Trevi Therapeutics Inc | TRVI | COM | $33,325,070 | 1,786,867 | SH | None |
| Oric Pharmaceuticals Inc | ORIC | COM | $32,470,419 | 2,998,192 | SH | None |
| Alphabet Inc | GOOGL | CAP STK CL A | $32,163,300 | 90,000 | SH | None |
| Dbv Technologies SA | DBVT | SPONSORED ADS | $30,460,737 | 1,857,362 | SH | None |
| Absci Corp | ABSI | COM | $28,682,515 | 2,474,764 | SH | None |
| Sionna Therapeutics Inc | SION | COM | $26,856,555 | 610,515 | SH | None |
| Rapport Therapeutics Inc | RAPP | COM | $26,730,013 | 641,469 | SH | None |
| Amylyx Pharmaceuticals Inc | AMLX | COM | $26,591,325 | 1,480,586 | SH | None |
| Annexon Inc | ANNX | COM | $25,458,869 | 4,458,646 | SH | None |
| Monopar Therapeutics Inc | MNPR | COM NEW | $25,010,226 | 270,118 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 2 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.